The best treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC)
is still debated. To guide clinical management of these patients and suggest the priorities for …

Docetaxel belongs to the class of taxane antineoplastic agents that act by inducing
microtubular stability and disrupting the dynamics of the microtubular network. The drug has …

Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly
Page 1 Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the …

Chemotherapy for elderly patients with non-small cell lung cancer (NSCLC) has been
questioned due to the perceived potential for higher toxicity in this population, possibly …

BACKGROUND: The objective of this study was to estimate antitumor activity and toxicity of
weekly docetaxel and gemcitabine as second-line chemotherapy for patients with recurrent …

Purpose: The aim of the present study was to identify elderly-specific clinical trials for
advanced non-small cell lung cancer (NSCLC) and to clarify the study design and patient …

Objectives To compare first-line treatment with docetaxel plus gemcitabine (DG) versus
gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer …

Background This open-label study compared docetaxel/gemcitabine vs.
paclitaxel/gemcitabine and a weekly (W) vs. 3-weekly (3 W) schedule in metastatic breast …

We present experience from a phase II randomized clinical trial, comparing standard
gemcitabine as monotherapy with low-dose gemcitabine in long infusion in a doublet with …

Elderly patients with advanced non-small cell lung cancer (NSCLC) are at higher risk for
adverse events related to treatment of their disease. Chemotherapeutic agents used alone …